ANI Pharmaceuticals, Inc. (ANIP)
Automate Your Wheel Strategy on ANIP
With Tiblio's Option Bot, you can configure your own wheel strategy including ANIP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
ANI Pharmaceuticals: A Short-Term Buying Opportunity
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new formulations of established drugs, minimizing launch expenses and maximizing market potential. INZIRQO and TEZRULY could generate significant revenue, with potential annual revenues of $1 billion and $350 million respectively, driving ANIP's PPS higher.
Read More
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.
Read More
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
3 Reasons Growth Investors Will Love ANI (ANIP)
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Read More
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Galectin Therapeutics Inc. (GALT) have performed compared to their sector so far this year.
Read More
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Expand Energy, Avista & Contango are well-poised to gain.
Read More
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to ANI Pharmaceuticals (ANIP) stock based on the movements in the options market lately.
Read More
5 Relative Price Strength Stocks to Navigate Today's Market
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
IHS, ANIP, MD, FMS and TREE are five stocks with explosive relative price strength.
Read More
5 High Earnings Yield Value Picks to Counter Market Uncertainty
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Unlock your portfolio value with high earnings yield stocks like ANI Pharma, Insteel, Pitney Bowes, IHS Holding and HighPeak Energy.
Read More
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross?
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals, Inc. (ANIP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ANIP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Read More
Wall Street Analysts Think ANI (ANIP) Could Surge 26.83%: Read This Before Placing a Bet
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for ANI (ANIP) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Relative Price Strength: A Smart Strategy Amid Market Turmoil
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
OOMA, ANIP, MATX, VIRT and EVER are five stocks with explosive relative price strength.
Read More
Wall Street Analysts Believe ANI (ANIP) Could Rally 32.4%: Here's is How to Trade
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for ANI (ANIP) points to a 32.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
Read More
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in a prefilled syringe format. This new presentation will be available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options through Cortrophin Gel's established specialty pharmacy network. The prefilled syringe reduces administration steps for patients using Cortrophin Gel, which remains available in 5 mL and 1 mL vials. For full indications and important safety information, please see below.
Read More
ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q4 2024 Earnings Conference Call February 28, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants David Amsellem - Piper Sandler Vamil Divan - Guggenheim Securities Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Oren Livnat - H.C. Wainwright Jeevan Larson - Truist Securities Glen Santangelo - Jefferies Operator Good morning, everyone.
Read More
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
BAUDETTE, Minn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and full year ended December 31, 2024.
Read More
ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates' 46 th Annual Institutional Investors Conference Tuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare Conference Tuesday, March 11, 2025, at 3:40pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com , under the Investors section under Events and Presentations.
Read More
About ANI Pharmaceuticals, Inc. (ANIP)
- IPO Date 2000-05-05
- Website https://www.anipharmaceuticals.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Nikhil Lalwani
- Employees 897